BioStock: Spago Nanomedical in hot area

Radionuclide therapies for cancer is a hot area that has been noticed through clinical advances, approved drugs and completed licensing deals. First North-listed Spago Nanomedical is in the process of entering clinical phase with its drug candidate ¹⁷⁷Lu-SN201, which is expected to have wide use in this particular area.

Read the article about Spago Nanomedical at biostock.se:

https://www.biostock.se/en/2022/09/spago-nanomedical-in-hot-area/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/